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Abstract 
Background: Non-Hodgkin lymphomas (NHL) are the most frequent hemato-oncological malignancies. Despite 
recent major advances in treatment, a substantial proportion of patients relapses highlighting the need for new 
therapeutic modalities. Promissory results obtained in pre-clinical studies are usually not translated when moving into 
clinical trials. Pre-clinical studies are mainly conducted in animals with high tumor burden; instead patients undergo 
chemotherapy as first line of treatment and most likely are under remission when immunotherapies are applied. Thus, 
an animal model that more closely resembles patients’ conditions would be a valuable tool.
Methods: BALB/c mice were injected subcutaneously with A20 lymphoma cells and after tumor development dif-
ferent doses of chemotherapy were assessed to find optimal conditions for minimal residual disease (MRD) establish-
ment. Tumor growth and survival, as well as drugs side effects, were all evaluated. Complete lymphoma remission was 
monitored in vivo using positron emission tomography (PET), and the results were correlated with histology. Immu-
nological status was assessed by splenocytes proliferation assays in NHL-complete remission mice and by analyzing 
tumor cell infiltrates and chemokines/cytokines gene expression in the tumor microenvironment of animals with 
residual lymphoma.
Results: Two cycles of CHOP chemotherapy at days 25 and 35 post-tumor implantation induced complete remission 
for around 20 days. PET showed to be a suitable follow-up technique for MRD condition with 85.7 and 75% of sensibil-
ity and specificity respectively. Proliferative responses upon mitogen stimulation were similar in animals that received 
chemotherapy and wild type mice. Tumors from animals with residual lymphoma showed higher numbers of CD4+ 
and CD8+ and similar numbers of NK, neutrophils and Tregs infiltrating cells as compared with non-treated animals. 
Gene expression of several cytokines as well as an array of chemokines associated with migration of activated T cells 
to tumor sites was upregulated in the tumor microenvironment of animals that received chemotherapy treatment.
Conclusions: We established a NHL-B pre-clinical model using standard chemotherapy to achieve MRD in immuno-
competent animals. The MRD condition is maintained for approximately 20 days providing a therapeutic window of 
time where new immunotherapies can be tested in conditions closer to the clinics.
Keywords: Non-Hodgkin lymphoma (NHL), Immunotherapy, Chemotherapy, CHOP, Clinical, Positron emission 
tomography (PET), Minimal residual disease (MRD)
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Background
Non-Hodgkin lymphomas (NHL) are the most frequent 
hemato-oncological malignancies. The current standard 
of care for NHL treatment is chemotherapy, radiotherapy 
and monoclonal antibodies (i.e. Rituximab) [1]. Although 
these combined treatments can achieve high rates of 
complete remission, a substantial proportion of patients 
relapses with chemoresistant disease. Survival rates for 
NHL vary depending on the age, performance status, his-
tological type, stage, (international prognostic index) IPI 
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Cancer Statistics Review (CSR), the overall 5-year relative 
survival rate for all ages is 69%, and the 10-year relative 
survival rate is 59%; 86% for follicular lymphoma, and 
61% for diffuse large B-cell lymphoma (DLBCL) [2].
Active immunotherapy is a promising complemen-
tary approach for NHL treatment. Induction of tumor-
specific adaptive immunity might generate long-lasting 
immunological memory able to prevent further relapses, 
and there is abundant literature demonstrating good 
rates of effectivity in pre-clinical models [3–5]. However, 
overall 85% of phase I–II clinical trials for novel treat-
ments in cancer fail; and of those that progress to phase 
III, only half become approved for clinical use [6]. Pre-
clinical NHL active immunotherapy studies are mainly 
performed in mice with high tumor burden that received 
no previous treatment, whereas clinical trials are per-
formed in patients that have undergone chemotherapy 
and they are in complete or partial remission [3, 7]. Thus, 
murine models usually do not resemble the clinical sce-
nario and this can be a major reason to explain the lack of 
consistency in results when moving into clinical trials [8]. 
The development of novel pre-clinical models that mimic 
the clinical setting could be valuable tool to explore new 
therapeutic strategies [9]. Particularly, it would be impor-
tant to have a model in which animals achieved com-
plete remission with chemotherapy and develop minimal 
residual disease (MRD) state.
We have previously assessed a murine NHL-B model 
where different immunotherapies were evaluated with 
promising results [10–12]. In the present study, we estab-
lish a new NHL-B pre-clinical model using standard 
chemotherapy (CHOP) to achieve complete response in 
immunocompetent animals. We believe that this model 
is more suitable to study new and optimized immuno-
therapies, thus it could be a valuable tool for pre-clinical 
studies that get closer to the clinics.
Methods
Animals and tumor cell line
Female BALB/c mice, 8–10  weeks old were used for 
in vivo experiments. Animals were housed on a 12:12 h 
light/dark cycles in racks with filtered air where food and 
water were given ad libitum.
The A20 cell line was derived from B lymphocytes of 
a naturally occurring reticulum cell sarcoma from an old 
BALB/cAnN mouse and was obtained from the Ameri-
can Type Culture Collection (Manassas, VA, USA). Cells 
were grown in RPMI-1640 medium (Sigma-Aldrich, St. 
Louis, MO) supplemented with 10% fetal bovine serum 
(PAN-Biotech, Aidenbach, Germany), 2 mM l-glutamine 
(Sigma) and 0.05  mM 2-mercaptoethanol (Sigma-
Aldrich, St. Louis, MO) (RPMI complete medium) at 
37 °C in 5% CO2 atmosphere.
Cell transplantation
For tumor challenge, A20 were grown in culture and har-
vested in log phase, washed and resuspended to a final 
concentration of 5  ×  106  cells/ml in PBS. 8–10  weeks-
old syngeneic female BALB/c mice were injected subcu-
taneously (s.c.) into the right flank with 1 × 106 cells in 
0.2 ml of PBS. Tumors were measured three times a week 
with a microcaliper in three dimensions, and tumor vol-
umes were calculated as length × width × depth × 0.523
6, as previously described [13]. Mice were euthanized by 
cervical dislocation when tumors reached 3000  mm3 or 
before if they showed signs of distress. These time points 
were defined as survival time.
Chemotherapy treatment for MRD lymphoma model
The standard chemotherapy regimen in patients for 
aggressive NHL as well as the most used regimen 
for indolent NHL is a combination of cyclophospha-
mide, doxorubicin, vincristine and prednisone/steroids 
(CHOP) given every 21  days for 6–8 cycles [1, 14]. We 
used a CHOP regimen to treat mice bearing lymphoma 
where oral prednisone was substituted by intraperitoneal 
(i.p.) dexamethasone in order to achieve more uniform 
levels of steroid and to reduce chemical peritonitis. In 
each chemotherapy cycle we used the following doses: 
cyclophosphamide 100  mg/kg i.p, doxorubicin 6  mg/kg 
i.p, vincristine 0.1 mg/kg i.p and dexamethasone 0.2 mg/
kg i.p. At day 25 post-tumor implantation (p.t.i.), groups 
of mice (n =  9) that were inoculated with A20 cell line 
were treated either with one cycle of chemotherapy 
(CHOP×1), two cycles of chemotherapy (CHOP×2) or 
PBS as control and were followed for tumor growth and 
survival. Side effects were monitored, through weight 
changes evaluation and hematological toxicity. Lympho-
cytes, monocytes and neutrophils recovery post-CHOP 
were evaluated in an automated blood cell counter and in 
peripheral blood smears. Blood was obtained using a 27G 
needle puncturing the tail vein. This allows us to select 
the optimal period between CHOP cycles.
To avoid potential infections, prophylactic anti-infec-
tious drugs (15  mg/kg of fluconazole and 20  mg/kg of 
acyclovir) were used during the neutropenia period.
Chemotherapy cytotoxicity
Cytotoxic effect of CHOP drugs on A20 tumor cell line 
was assessed in vitro by growth inhibition studies. Cells 
were seeded in 24-well plates at a density of 1 × 106 via-
ble cells per well. Triplicate wells were treated with dif-
ferent concentrations of the drugs or PBS and Dimethyl 
sulfoxide (DMSO) as controls (Sigma-Aldrich, St. Louis, 
MO). Cyclophosphamide, doxorubicin, and dexametha-
sone were tested 0.1, 1, 10, 100 nM and 1 µM, and Vin-
cristine was tested 10, 20, 30, 40, 50 and 70  nM. Plates 
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were incubated at 37  °C in a humidified incubator with 
5% CO2 for 96  h. Then, all cultures were monitored for 
cell viability using Trypan blue vital stain (Life Technolo-
gies, Carlsbad, CA), and Annexin V (BD Pharmingen, San 
Diego, CA) with Propidium iodide (PI) (Sigma-Aldrich, 
St. Louis, MO). The half maximal inhibitory concentra-
tion (IC50) was calculated as the concentration (nM) that 
causes half of the cell mortality.
To evaluate in  vivo toxicity, body weight was meas-
ured before and after CHOP administration. The body 
weight change (BWC) was calculated using the follow- 
ing formula:  BWC (%) =
[(
body weight on the last day
)
− (




body weight on day 0
)
×100(%) , 
as previously described [15].
Necropsy and histology
Mice were sacrificed at day 45 p.t.i. and necropsies were 
performed. Animals were examined macroscopically for 
lymphoma infiltration at primary sites or lymph nodes or 
other organs. Primary lymphoma site, inguinal and retro-
peritoneal lymph nodes, liver and spleen were removed 
and immersed in formalin buffered 10% at room tem-
perature for 24 h. Organs were washed with PBS for 24 h 
at 4 °C and then immersed successively two times for 2 h 
in EtOH 95%, absolute alcohol, Xylol, paraffin and pro-
cessed in paraffin blocks. Sections of 4 µm were cut and 
dewaxing immersed successively two times for 5 min in 
xylol and absolute alcohol, one time for 5 min in EtOH 
95% and EtOH 90%. Then sections were washed three 
times with distilled water and stained with hematoxylin-
eosin. Finally, sections were immersed successively for 
3  s in EtOH 70%, EtOH 80%, EtOH 95%, absolute alco-
hol and Xylol, and assembled with Canada balsam. These 
sections were microscopically evaluated to detect lym-
phoma infiltration.
PET/CT imaging
Complete lymphoma remission was evaluated by in vivo 
imaging using positron emission tomography/com-
puted tomography (PET/CT) scan with 18F-2-fluor-2-
desoxi-d-glucosa (18F-FDG) as radiotracer. The study 
was performed in the Centro Uruguayo de Imagenología 
Molecular (CUDIM).
Image acquisition
PET/CT imaging in mice was performed using a tri-
modality scanner (Triumph, Trifoil, Inc., US) with 
LYSO/LGSO scintillators (spatial resolution: 1.0  mm 
and an axial field of view: 3.75 cm). Data were acquired 
in list mode in a 184 × 184 × 31 matrix with pixel size: 
0.25  ×  0.25  ×  1.175  mm; coincidence window width: 
22.22 s.
Seventeen mice were evaluated by PET/CT, of which 
two died later on as result of cytotoxicity and thus were 
excluded from the analysis. Images were obtained before 
(day 25 p.t.i.) and after CHOP treatment when mice were 
in complete clinical remission (day 44 p.t.i.). The animals 
were anesthetized with 2% isofluorane in an oxygen flow 
of 2  l/min, placed in prone position on the scanner bed 
and injected via the caudal vein with 100 µl of (18F-FDG) 
(20  ±  5.4  MBq). PET images (static studies) acquisi-
tion started 30 min after radiotracer administration and 
performed over 60  min. Sinograms were reconstructed 
using 3D maximum likelihood expectation maximization 
(3D-MLEM).
Image analysis
Semi-quantitative analysis was done using PMOD soft-
ware version 3.4 (PMOD Technologies, Ltd., Zurich, 
Switzerland). PET studies were co-registered with the 
corresponding CT scan studies for anatomical localiza-
tion. Images were displayed as coronal, sagittal and axial 
slices.
For quantifying the specific uptake, volumes of inter-
est (VOIs) were drawn manually on tumor as target (T) 
and skeletal muscle as non-target tissue (NT) [16]. The 
activity uptake was expressed as KBq/cc; results were 
expressed as T/NT.
Splenocyte proliferation assay
At day 45 p.t.i. mice in complete remission from 
CHOP×2 group as well as mice from PBS control were 
sacrificed and spleens were removed. Spleens were dis-
rupted and prepared as a single-cell suspension. Spleno-
cytes were stained with 1 µM of 5(6)-carboxyfluorescein 
diacetate N-succinimidyl ester (CFSE) (Sigma-Aldrich, 
St. Louis, MO). CFSE labeled splenocytes were incu-
bated at 37 °C with 5% CO2 in 24 wells plate at 2 × 106 
cells/ml density by triplicates in complete medium for 
4 days and were stimulated with 1 µg/ml of Concanava-
lin A (ConA) (Sigma-Aldrich, St. Louis, MO) or non-
stimulated. After the incubation, cells were washed and 
stained with PI for 10 min in the dark at room tempera-
ture. Data were acquired by flow cytometry (FACS Canto 
II, Becton–Dickinson) and were analyzed with ModFit 
software (Verity Software House, Inc). For analysis, viable 
cells were gated based on FSC and PI profiles. The parent 
generation was set as the median fluorescence intensity 
using non-stimulated control sample.
Flow cytometry analysis of tumor‑infiltrating cells
At day 45 p.t.i. mice with residual primary lymphoma 
from CHOP×2 group (i.e. animals with partial response 
to chemotherapy) as well as PBS control, were sacrificed 
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and tumors were removed and prepared as a single-cell 
suspension. Cells were immunostained at 4  °C in the 
dark for 30  min with the following panel of antibodies: 
FITC-conjugated anti-CD49b, PECy7-conjugated anti-
CD8, APC-conjugated anti-CD3, APCCy7-conjugated 
anti-CD4, PerCPCy5.5-conjugated anti-CD19, FITC-
conjugated anti-CD4, PE-conjugated anti-FoxP3, PECy7-
conjugated anti-CD3, APC-conjugated anti-CD25, 
FITC-conjugated anti-Ly6C, PE-conjugated anti-Ly6G, 
(all reagents from BD Pharmingen, San Diego, CA). Opti-
mal antibody concentration was previously defined by 
titration. For intracellular FoxP3 staining, cells were first 
stained with anti-CD4 and anti-CD25 antibodies, then 
fixed and permeabilized with a mouse FoxP3 buffer set 
(BD Pharmingen) according to the manufacturer’s pro-
tocols. Cells were washed twice with permeabilization 
buffer and then incubated with anti-FoxP3 at 4  °C for 
30 min in the dark. Flow cytometry data were collected 
on a FACS Canto II flow cytometer equipped with two 
lasers (Becton–Dickinson, Oxford, UK). For data acqui-
sition and analysis, FACSDiva (Becton–Dickinson) and 
Infinicyt (Cytognos, Spain) software were used.
Determination of cytokines and chemokines in tumor 
microenvironment
Tumor microenvironment cytokines and chemokines 
mRNA levels were determined using quantitative reverse 
transcription-PCR. At day 45 p.t.i mice from PBS and 
CHOPx2 group, in which primary tumor persisted 
(partial remission), were sacrificed and tumors were 
removed, immersed in Trizol reagent (Invitrogen, Carls-
bad, CA) and stored at −80  °C until processed. Tumors 
were homogenized with an Ultra Turrax T8 homogenizer 
(IKA-Werke, Staufen, Germany) and RNA was extracted 
according to the manufacturer’s instructions. RNA qual-
ity and quantity were assessed by spectrophotomet-
ric measurements at 260/280  nm in a NanoDrop 2000 
(Thermo Fisher Scientific, Waltham, MA). Before cDNA 
synthesis, 1 µg total RNA was treated with DNase I (Inv-
itrogen), and first-strand cDNA synthesis was carried out 
using random primers (Invitrogen) and Moloney murine 
leukaemia virus reverse transcriptase (Invitrogen). Real-
Time PCR (RT-PCR) was performed using a QuantiTect 
SYBR green PCR kit (Qiagen, Hilden, Germany) in a 
7900HT RT-PCR System (Applied Bio- systems, Foster 
City, CA). B2m gene was used as housekeeping gene. The 
primers used are listed in Table 1 and were used at a final 
concentration of 0.9 µM. The relative mRNA amount in 
each sample was calculated using the 2−ΔΔCt method [17], 
where Ct = Ctgene of interest− CtB2m, and expressed as 
relative mRNA levels in the test group compared with the 
control group (fold change).
Statistical analysis
Results were analyzed in SPSS 17.0 (Statistical Pack-
age for the Social Sciences) for Windows. Differences 
in survival times were determined using Kaplan–Meier 
and log-rank test. For tumor growth and in vitro assays 
the statistical significance of differences between study 
groups were analyzed using Student’s t-test and analysis 
of variance (ANOVA). A value of p < 0.05 was considered 
statistically significant.
Receiver operating characteristic curve (ROC) was 
used to evaluate the T/NT ratio in the diagnosis of com-
plete remission by assessing the area under the ROC 
curve (AUC), sensitivity, and specificity. The cut-off point 
was determined by maximizing the sum of sensitivity and 
specificity; histology was used as a gold standard variable.
Results
Chemotherapy efficacy and in vivo toxicity
First, we assessed the bioactivity of the cytostatic drugs 
on the A20 tumor cell line. The in  vitro IC50 values 
obtained for doxorubicin and vincristine were 25 and 
1 nM respectively, which are similar to the reported IC50 
values of these two drugs on other tumor-sensitive cell 
lines, confirming the possibility of using them on the 
lymphoma model. Our results also confirmed that cyclo-
phosphamide and dexamethasone cannot be evaluated 
in vitro since they both requires hepatic activation [18].
We then treated A20-bearing animals with increas-
ing doses of CHOP starting with doses used in a previ-
ously reported xenograft lymphoma model [19]. Those 
particular doses did not show any anti-tumor effect on 
A20-bearing immunocompetent animals, so we doubled 
them and found that they were too toxic and all ani-
mals succumbed to the treatment (results not shown). 
Thus, we decided to assess intermediate values and to 
apply two cycles separated ten days apart. This interval 
between cycles was decided based on results from white 
blood cells peripheral count that demonstrated complete 
bone marrow regeneration at day 10 post-chemotherapy. 
Overall, these studies provided us with an optimal CHOP 
doses regime for treatment as described in Methods. At 
these particular doses, animals had an acceptable toler-
ance to chemotherapy. Particularly, no animals died with 
one cycle of CHOP, while 18% of animals receiving two 
cycles of CHOP died by chemotherapy cytotoxicity. Low 
levels of toxicity were also evidenced by variations in 
body weight over time (Fig. 1a). The highest decrease in 
weight was observed ten days after second CHOP cycle, 
and after that, animals started to recover towards average 
normal body weight. Cachexia was not observed at any 
time after CHOP administration. Transient neutrope-
nia and monocytopenia were observed post CHOP, but 
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normal values were recovered by day 10–15. Both CHOP 
cycles induced transient myelosuppression (Fig.  1b). 
Instead, lymphocytes levels in blood also decreased 
after CHOP, and values did not return to previous values 
within the time frame of the experiments.
All in all, these results showed that we had found a suit-
able chemotherapy treatment with reasonable toxicity 
levels.
Tumor development and survival rate
We then evaluated the effect of the selected CHOP 
regimen on tumor development and survival. As previ-
ously shown by us [10], A20-bearing animals that do 
not receive any treatment show sustained tumor growth 
over time and a median survival of around 35 days. On 
the contrary, animals receiving either one or two doses 
of chemotherapy showed a decrease in tumor growth 
from day 25 p.t.i., starting immediately after the first 
CHOP cycle (Fig. 2a). Mice receiving a single CHOP dose 
had a period when tumor volume decreases and it was 
close to zero, but this status lasted only for a few days. 
Instead, in the group of animals receiving two doses of 
CHOP, around 92% of animals showed clinical complete 
remission of the primary tumor for a longer period of 
approximately 20  days (Fig.  2a, b). After that tumors 
started to grow again and eventually all mice died for 
lymphoma disease. Reasons of death among the animals 
depended of the particular treatment group and were 
either drug toxicity or respiratory distress, most likely 
due to metastasis, or the animals where euthanized for 
ethical reasons when the tumor reached a pre-defined 
volume size of 3000 mm3 (Table 2). Survival among ani-
mals receiving any chemotherapy regimen was extended, 
but it was significantly higher among animals receiving 
two cycles of chemotherapy (Fig. 2c).
Evaluation of remission in treated animals
Histology
A major aim of our work was to develop a lymphoma 
MRD model as a more suitable model for immunother-
apy assessment. For this, we treated the animals with two 
doses of CHOP and achieved complete clinical remission 
during a period of around 20 days. To confirm complete 
remission in these animals, five mice per group were 
euthanized at day 45 p.t.i. to perform necropsies and his-
tological analysis. Macroscopically, control animals (no 
Table 1 Sequences of primers used for quantitative RT-PCR
Gene Forward primer (5′–3′) Reverse primer (5′–3′) Product length (bp)
B2m CCTGCAGAGTTAAGCATGCCAG TGCTTGATCACATGTCTCGATCC 72
Ccl2 CCCTCAACGGAAGAACCAAA CACATCAGGTACGATCCAGGC 72
Ccl3 AACATCATGAAGGTCTCCAC CCAAGACTCTCAGGCATTCA 294
Ccl4 GCCCTCTCTCTCCTCTTGCT GTCTGCCTCTTTTGGTCAGG 196
Ccl5 GGTACCATGAAGATCTCTGCA AAACCCTCTATCCTAGCTCAT 294
Ccl20 TTTTGGGATGGAATTGGACAC TGCAGGTGAAGCCTTCAACC 69
Cxcr4 TTCTCATCCTGGCCTTCATC CTTTTCAGCCAGCAGTTTCC 92
Cxcr7 GCCGTACCATTTTGTGGTTC TGCAACGCTGTAAAGAGCAC 96
Cxcl1 CTTGGTTCAGAAAATTGTCCAAAA ACGGTGCCATCAGAGCAGTCT 84
Cxcl9 TGGAGCAGTGTGGAGTTCGA CCTCGGCTGGTGCTGATG 73
Cxcl10 GCCGTCATTTTCTGCCTCAT GCTTCCCTATGGCCCTCATT 127
Cxcl11 CAAAATGGCAGAGATCGAGAAA TGAGCCTTCATAGTAACAATCACTTCA 87
Cxcl12 GAAGTGGAGCCATAGTAATGCC TCCAAGTGGAAAAATACACCG 133
Cxcl13 CAACTGTTGTCGGTCTAAACATCAT GGTCCAGATCACAACTTCAGTTTTG 89
Gal-1 (Galectina-1) TGAACCTGGGAAAAGACAGC TCAGCCTGGTCAAAGGTGAT 190
Il2 CCTGAGCAGGATGGAGAATTACA CTTTCAATTCTGTGGCCTGCTTGGG 92
Il4 ACAGGAGAAGGGACGCCAT GAAGCCCTACAGACGAGCTCA 95
Il6 GTTCTCTGGGAAATCGTGGAAA AAGTGCATCATCGTTGTTCATACA 78
Il10 CATTTGAATTCCCTGGGTGAGA TGCTCCACTGCCTTGCTCTT 101
Il12 ATCACACGGGACCAAACCA CAGGCAACTCTCGTTCTTGTGTAGT 74
Il17a CTCCAGAAGGCCCTCAGACTAC GGGTCTTCATTGCGGTGG 69
Ifng TCAGCAACAGCAAGGCGAAA CCGCTTCCTGAGGCTGGAT 143
Tgfb GCTGAACCAAGGAGACGGAAT GAGTTTGTTATCTTTGCTGTCACAAGA 76
Foxp3 CCCAGGAAAGACAGCAACCTT TTCTCACAACCAGGCCACTTG 89
Tnfa CATCTTCTCAAAATTCGAGTGACAA CCTCCACTTGGTGGTTTGCT 63
Page 6 of 13Bascuas et al. J Transl Med  (2016) 14:323 
treatment) showed disseminated disease with extensive 
lymph nodes and/or hepatic involvement (Fig. 3a). There 
were lymphoma infiltrations at inguinal and retroperi-
toneal lymph nodes. Instead, CHOP×2 animals did not 
show any disseminated disease (Fig. 3b). We also evalu-
ated by histology the primary tumor site, draining lymph 
nodes, retroperitoneal lymph nodes, spleen, liver and 
other tissues of abnormal appearance in order to evaluate 
lymphoma infiltration. Hematoxylin-eosin stained sec-
tions demonstrated tumor tissue consisting of a diffuse 
growth pattern with large and cohesive tumor cells with 
pleomorphic nuclei resembling centroblast and some 
small/medium size centrocyte-like cells. Numerous small 
vessels (capillaries and arterioles) were visible among the 
tumor cells (Fig. 4). These cells were histological similar 
to human DLBCL. Liver involvement was 76 and 11% for 
control and CHOP×2 groups respectively as evaluated 
by histology. Liver lymphoma infiltration was character-
ized by atypical large lymphoid cells with central perive-
nous distribution within the liver parenchyma (Fig. 4d).
PET‑CT evaluation
Advanced imaging techniques can improve disease 
assessment, not least because they allow response evalu-
ation to treatment and follow-up without the need of 
sacrificing animals. We evaluated PET as an alternative 
for in  vivo monitoring of the disease. For this, we first 
demonstrated glucose analogue (18F-FDG) uptake by A20 
lymphoma cells in tumor-bearing mice confirming that 
18F-FDG was a good radiotracer for PET imaging in A20 
model.
PET-CT imaging was performed before (day 25 p.t.i.) 
and after (day 45 p.t.i.) CHOP treatment in order to 
evaluate 18F-FDG uptake and to confirm the complete 
remission (MRD negative status). Post-chemotherapy, T/
NT cut-off value was set to 2.45 and calculated using a 
ROC curve with histology as a gold standard. T/NT val-
ues of 2.45 or more were considered residual lymphoma 
disease. The AUC reached 0.74 (95% CI 0.6–0.991), with 
a sensitivity of 85.7% and specificity of 75%. Consider-
ing this cut-off value, pre-CHOP imaging (day 25 p.t.i.) 
indicated primary tumor uptake without metastasis as 
expected (Fig. 5a). On the other hand, post-CHOP PET 
image analysis (day 45 p.t.i.) revealed complete remis-
sion in many animals (Fig.  5b). Other mice had uptake 
at the site of the primary tumor (Fig.  5c), in disagree-
ment with the histology result, suggesting the existence 
of false positive. Animals that had residual primary 
tumor after CHOP×2 treatment also presented retrop-
eritoneum and liver 18F-FDG uptake (Fig. 5c) evidencing 
the existence of metastasis in accordance with histology 
results.
Immunological status after chemotherapy treatment
In order to assess the immunological status of CHOP-
treated animals, five mice per group were sacrificed at 
day 45 p.t.i. and spleens were removed for proliferation 
assays. As shown in Fig.  6, mice in complete remission 
showed similar proliferation rate upon mitogen stimula-
tion than control mice (PBS).
Additionally, mice with residual lymphoma (partial 
response) post CHOP×2 treatment were also sacrificed 
at day 45 p.t.i., and the primary tumor was removed to 
evaluate tumor-infiltrating populations. Animal from 
CHOP×2 group showed significantly higher numbers of 
CD4+ (p = 0.0023) and CD8+ (p = 0.0034) tumor-infil-
trating T cells as compared with animals from the control 
group (Fig.  7). Numbers of NK cells, regulatory T cells 
Fig. 1 In vivo CHOP toxicity. a Percentage of body weight change 
(BWC) is shown for PBS, CHOP×1 and CHOP×2 groups. b Peripheral 
white blood cells counts. Absolute values for monocytes, neutrophils 
and lymphocytes are shown for untreated (PBS group), treated ani-
mals, 5 and 10 days post- first CHOP cycle (CHOP×1 d.5 and CHOP×1 
d.10, respectively) and 7 and 15 days post- second CHOP cycle 
(CHOP×2 d.7 and CHOP×2 d.15, respectively)
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(Treg) and neutrophils cells in the tumors were similar 
in treated and non-treated animals. Analysis of cytokines 
and chemokines mRNA levels in the tumor microenvi-
ronment of animals with partial response to chemother-
apy showed significant increases in mRNA levels for Ccl3, 
Ccl4, Ccl5, Cxcl9, Cxcl12, Il2, Il12 and Ifng whereas Cxcr4 
and Tgfb gene expression were significantly repressed as 
compared with tumors from untreated mice (Fig. 8).
Discussion
Therapies against NHL have achieved substantial suc-
cess in the last few years [2, 3], but rates of relapse are 
still high fostering the research on new therapeutic 
approaches. Animal models are essential for research and 
development of novels immunotherapies, and the use of 
well-characterized inbreed laboratory mice is most likely 
one of the best experimental systems for cancer research. 
Cancer development has similar physiologic characteris-
tics in mice and humans with the acquisition of mutations 
in equivalents oncogenes and suppression genes [20, 21]. 
Xenograft models are widely used to demonstrate pre-
clinical activity of drugs prior clinical evaluation, but 
they are not adequate for testing immunotherapies or 
studying tumor microenvironment because these require 
immunocompetent mice [9]. Also, in order to more accu-
rately predict human responses NHL immunotherapies 
should be tested in a similar context to that usually found 
Fig. 2 Tumor growth and animal survival in MRD model. a Tumor volume (mm3) was measured every 2–3 days. Results are shown as 
mean ± standard deviation (n = 9). CHOP cycles are indicated with arrows. b Tumor volume (mm3) at day 41 p.t.i. Each dot represents one individ-
ual animal. Mean and standard deviation are also depicted. Significant differences were observed between all groups (p < 0.0001). c Animal survival 
was followed up for 120 days. Significant differences were observed between all groups (log rank, p < 0.0001)
Table 2 Percentage of animal death related to drug resist-
ance, metastatic disease and primary tumor
NA not applicable
PBS CHOP×1 CHOP×2
Drug toxicity NA 0% 18%
Metastatic disease 0% 25% 47%
Primary tumor (>3000 mm3) 100% 75% 35%
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Fig. 3 Necropsy of chemotherapy-treated and untreated animals at day 45 p.t.i. a Untreated mouse: retroperitoneal (1) and hepatic (2) involvement 
are indicated with arrows. b CHOP×2-treated mouse in complete remission
Fig. 4 Histological study of MRD. a Primary tumor sections from a control mouse (PBS group): NHL-B histology is observed and corresponds to a 
diffuse infiltration by centrocytes and centroblasts with a starry sky pattern, due to high proliferation rate. b Retroperitoneal sections from a mouse 
where NHL disease persists post-chemotherapy: similar histology of primary tumor is observed. c Liver sections from a mouse with complete 
remission: typical healthy hepatic architecture with the centrilobular veins and hepatic sinusoids is observed. d Tumor-infiltrated liver sections from 
a mouse where NHL disease persists post-chemotherapy: infiltrating tumor cells are observed in portal field. e Spleen section from mouse with 
complete remission: normal architecture with the white and red pulp is observed
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in humans, which for most of the cases implies chem-
otherapy-treated patients. Chemotherapy can modu-
late distinct features of tumor immunobiology and the 
optimal integration of immunotherapies with standard 
chemotherapies to minimize antagonistic interactions 
and engage potential synergies is a major challenge [22]. 
Ideally, immunotherapy should be applied in the setting 
of MRD, after the tumor mass has been reduced with sys-
temic chemotherapy. This strategy should minimize the 
negative impact of tumor bulk on the immune response 
and might work potentiating the immunological effects 
of chemotherapy. Indeed, the use of immunotherapy 
associated with traditional agents, as combination ther-
apy, is now the standard for treatment of many types of 
cancer, improving clinical outcomes.
Many clinical trials with vaccines against NHL have 
shown anti-tumoral responses after achieving complete 
or partial remission with chemotherapy [3, 5, 23, 24]. For 
all these reasons, we propose that pre-clinical investiga-
tion in NHL should be attempted in a murine model that 
mimics that clinical setting.
The four-drug combination CHOP (cyclophosphamide, 
doxorubicin, vincristine, and steroids) with Rituximab 
has become the “standard” first line treatment for aggres-
sive NHL (most frequently diffuse large B cell lymphoma) 
and it is the most used regimen for treat indolent lym-
phoma [1, 14, 25, 26]. In order to define more suitable 
pre-clinical conditions, we assessed the use of CHOP to 
generate a new model in A20-bearing animals that more 
closely resemble the clinical scenario. First, we tested 
the in vitro sensitivity of A20 cells to CHOP drugs. We 
found that the IC50 for doxorubicin and vincristine in 
A20 cells were similar to those reported by Dijoseph 
et al. in other lymphoma cell line [18]. Since cyclophos-
phamide and dexamethasone could not be evaluated 
because they require hepatic activation, we then tested 
Fig. 5 Positron emission tomography (PET) study of MRD. a A20 tumor-bearing mouse at day 25 p.t.i. (pre-CHOP treatment). Primary tumor FDG 
uptake is observed. Volumes of interest (VOI) are shown with circles: primary tumor (blue) and muscle (skyblue). T/NT: 4.5. b Animal with complete 
tumor remission at day 45 p.t.i. (post-CHOP treatment). FDG uptake is below detection level in primary tumor or in any organs. c Animal without 
tumor remission at day 45 p.t.i. (post-CHOP treatment). Primary tumor and hepatic metastasis are observed. VOIs are shown with circles: primary 
tumor (blue), hepatic metastasis (red) and muscle (sky-blue). T/NT: 4.0, liver/muscle ratio: 3.3. 1 axial section; 2 saggital section, and 3 coronal section
Fig. 6 Splenocyte proliferation assay. Mice from PBS and CHOP×2 
groups were sacrificed at day 45 p.t.i., and spleens were removed 
for splenocyte proliferation assay. Splenocytes were labeled with 
CFSE and cultured for 4 days with Concanavalin A (ConA) or left 
unstimulated. The percentage of proliferation cells for each condi-
tion was determined as described in M&M. Results are shown as the 
mean ± standard deviation (n = 5)
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the combination of drugs in vivo in A20-bearing animals, 
and found that a two-cycles drug schedule induces lym-
phoma remission for at least 20 days (MRD status) in a 
highly reproducible way. This schedule was well tolerated 
with transient and mild neutropenia and body weight 
loss.
We also found that administration of chemotherapy 
did not resulted in immunosuppression in A20-bearing 
animals. Cancer chemotherapy was historically consid-
ered as promoting immunosuppression, but recent stud-
ies have demonstrated that certain chemotherapies can 
instead augment tumor immunity in addition to their 
cytotoxic effect. Chemotherapy can promote anti-tumor 
immune responses by increasing the immunogenicity 
of malignant cell, or by inhibiting immunosuppressive 
circuits that are established by cancer [27–29]. Some 
chemotherapy drugs at their standard dose mediate their 
tumor effect, at least in part, by inducing immunogenic 
cell death, which involves the release of tumor antigens 
and danger-associated molecular patterns (DAMPs) in 
the tumor microenvironment, resulting in a proinflam-
matory microenvironment, where specific anti-tumor 
immunity may be developed [28]. It has also been dem-
onstrated that chemotherapy can modulate the activity of 
immune T-cell subsets decreasing the number of Tregs 
cells, shifting CD4+ T helper phenotype from type 2 to 
type 1, inducing the differentiation of Th17 cells, and pro-
moting the evolution of a durable T-cell memory [28]. 
We found that animals receiving the two CHOP doses 
(CHOP×2 group) have higher numbers of CD4+ and 
CD8+ T cells recruited to the tumor as well as a signifi-
cant increase in Il12 and Ifng and a decrease in Tgfb gene 
expression reinforcing the idea that CHOP treatment 
may indeed stimulate the development of effective anti-
tumor immunity [30].
Increasing evidence indicates that the tumor micro-
environment has critical roles in all aspects of cancer 
biology, including growth, angiogenesis, metastasis 
and progression. In this regard, it is recognized that 
chemokines and their receptors, originally identified 
as mediators of inflammatory diseases, serve as critical 
communication bridges between tumor cells and stro-
mal cells to create a permissive microenvironment for 
tumor growth and metastasis [31–34]. In melanoma, it 
has been demonstrated that up regulation of expression 
of several chemokine genes such as Ccl2, Ccl3, Ccl4, Ccl5, 
Cxcl9, and Cxcl10 in the tumor microenvironment cor-
relates with the recruitment of activated effector T cells 
to the tumor increasing antitumor immunity [35]. Con-
versely, it has also been reported low amount of these 
chemokines in poorly infiltrated melanomas and colorec-
tal carcinomas [35–37]. Our results showing a significant 
increase in Ccl3, Ccl4, Ccl5 and Cxcl9 genes expression 
in CHOPx2 group versus PBS group at day 45 p.t.i. are 
in accordance with those previously reported results, 
and confirm that in our model post-chemotherapy mice 
are fully immunocompetent. Furthermore, in CHOP×2 
group we found a significant increase in Cxcl12 expres-
sion but not in expression of its receptor cxcr4. The 
CXCL12–CXCR4 biological axis has been associated 
Fig. 7 Tumor-infiltrating cells. Mice from PBS and CHOP×2 groups were sacrificed at day 45 p.t.i., and tumors were removed to study tumor-
infiltrating cell populations. Percentage of CD4+ T cells (CD3+ CD4+ lymphocytes), CD8+ T cells (CD3+ CD8+ lymphocytes), NK cells (CD3− CD49b+ 
lymphocytes), Tregs (CD3+ CD4+ CD25+ FoxP3+ lymphocytes), and neutrophils (Gr1+ CD11b+ cells), determined by flow cytometry. Results are 
shown as mean ± standard deviation (n = 5). Significant differences between groups were observed for CD4+ (p = 0.0023) and CD8+ T cells 
(p = 0.0034)
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Fig. 8 Cytokine/chemokine gene expression levels in the tumor microenvironment. Mice from PBS and CHOP×2 groups were sacrificed at day 
45 p.t.i., and tumors were removed to assess the expression of cytokine and chemokines genes by quantitative RT-PCR on total tumor RNA. Gene 
mRNA values were normalized to that of B2m mRNA, and the results are expressed relative to mRNA levels in the PBS group. Results are shown 
as mean ± standard deviation (n = 5). Significant differences were observed for Ccl3, Ccl4, Ccl5, Cxcr4, Cxcl9, Cxcl12, Il2, Il12, Ifng and Tgfb genes 
(p < 0.05)
Page 12 of 13Bascuas et al. J Transl Med  (2016) 14:323 
with tumor invasion and metastases. In fact, CXCR4 is 
the most common chemokine receptor overexpressed in 
human cancer [32].
To confirm remission and monitored the disease an 
in vivo imaging system (PET) was applied in our model. 
When tumor cannot be detected clinically the use of 
PET post-chemotherapy allows a diagnosis of complete 
remission. PET is a minimal invasive technology easy to 
perform on anaesthetized mice, offering serial dynamic 
observations of tumor development in the same ani-
mal. In recent years, the use of PET in the diagnosis and 
monitoring of NHL patients, as well as other types of 
cancer, has increased [30, 38]. The most frequent radi-
otracer used in oncology is the glucose analogue FDG 
labelled with the positron-emitting radionuclide 18F. 
Several studies have demonstrated 18F-FDG increased 
uptake in most lymphomas, with a good correlation 
between intensity uptake, malignancy and proliferation 
activity [39]. Chaise et al. demonstrated the feasibility of 
PET using 18F-FDG in high-tumor burden A20 murine 
model [40]. In this study we could evaluate the treat-
ment response detecting intra-abdominal lymphoma 
and hepatic involvement. There was a good correla-
tion between PET images and histology. To the best of 
our knowledge, our study is the first to assess the value 
of FDG-PET for in  vivo evaluation of post-chemother-
apy remission in a murine NHL model. In patients, it is 
accepted that post-chemotherapy inflammatory reac-
tions increase the rate of false positives results obtained 
with PET. To minimized this in NHL patient the PET 
scan should be performed after at least 3  weeks post-
chemotherapy [41]. A meta-analysis performed by Zijl-
stra et  al. revealed a pooled sensitivity and specificity 
of 72% (95% CI 61–82%) and 100% (95% CI 97–100%), 
respectively [42]. In our PET studies we reached a good 
sensitivity (85.7%) whereas specificity was 75%. The 
lower specificity results compared with data reported in 
human could be explained by the remaining inflamma-
tion at the time of our analysis.
Overall, we describe a NHL-B MRD syngeneic murine 
model as a novel tool to evaluate immunotherapies effec-
tiveness as well as to study tumor microenvironment in 
relapse lymphoma. This model is unique in many aspects, 
inasmuch: (a) it uses fully immunocompetent mice; (b) 
remission is obtained by CHOP chemotherapy using 
the same cytostatic drugs that are the first line standard 
treatment for NHL in humans; (c) lymphoma complete 
remission is reached and maintained for a reasonable 
therapeutic window (20  days) where immunotherapies 
can be tested; (d) animals remains immunocompetent 
despite chemotherapy; (e) it uses an in vivo imaging sys-
tem to follow disease evolution that correlates well with 
histology as gold standard.
Conclusions
We have developed a novel pre-clinical model for NHL 
lymphoma that resembles more closely the situation 
found in humans, providing a therapeutic window where 
immunotherapies can be tested in conditions closer to 
those found in patients. We feel that the availability of 
such a model provides an important tool for evaluating 
new immunotherapies and will help to bridge the gap 
between pre-clinical models and clinical trials.
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